FGFR1 and neoplasm: A novel FGFR1 inhibitor, CYY292, showed promising results in inhibiting tumor growth by inhibiting the Akt/GSK3β/snail signaling axis in glioblastoma [118]; Pemigatinib was also found to induce a partial response along with neurological improvement [119].